The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

The Global Antibacterials Market: R&D Pipelines, Market Analysis and Competitive Landscape

The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.

This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.

The following product classes are analyzed in this report:

• aminoglycosides
• carbapenems
• cephalosporins
• dihydrofolate reductase inhibitors
• glycopeptides
• ketolides
• lipopeptides
• macrolides
• penicillins
• oxazolidinones
• pleuromutulins
• quinolones

The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.

The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.

Key Features of this report:

• Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.
• In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.
• Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.
• Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.
• Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.

 
 

1 EXECUTIVE SUMMARY

2 INTRODUCTION TO BACTERIAL DISEASES
2.1 Group A Streptococcus (GAS)
2.2 Group B Streptococcus (GBS)
2.3 Streptococcus pneumoniae
2.4 Haemophilus Influenzae
2.5 Neisseria Meningitidis
2.6 Methicillin Resistant Staphylococcus Aurens (MRSA)

3 PATIENT DEMOGRAPHICS
3.1 Group A Streptococcus (GAS) Patient Statistics
3.2 Group B Streptococcus (GBS) Patient Statistics
3.3 Streptococcus pneumoniae Patient Statistics
3.4 Haemophilus Influenzae Patient Statistics
3.5 Neisseria Meningitidis Patient Statistics
3.6 MRSA Patient Statistics

4 KEY DRIVERS
4.1 Drug Resistance
4.2 New Treatments
4.3 Patient Demographics
4.4 Vaccines
4.5 Potential for Clinical Success
4.6 Indirect Cost Associated with Infectious Diseases

5 KEY RESISTORS
5.1 Over-prescription
5.2 Antibiotic Resistance Leading to Short Antibacterial Drug Lifecycles
5.3 Acute Use of Antibiotics
5.4 Generics
5.5 Curative Therapies and Vaccines

6 THE MARKET
6.1 The Global Anti-infective Market
6.2 Market Segments
6.3 Global Antibacterial Market
6.3.1 Cephalosporin Antibiotics
6.3.2 Macrolide Antibiotics
6.3.3 Penicillin Antibiotics
6.3.4 Quinolone Antibiotics
6.3.5 Other Antibiotics
6.4 The Major Players
6.4.1 Antibacterial Major Players in 2006
6.4.2 Antibacterial Major Players in 2012
6.5 Market Trends
6.5.1 Antibacterial Agents by 2012

7 LEADING ANTIBACTERIAL DRUG CLASSES
7.1 Aminoglycosides
7.2 Carbapenems
7.3 Cephalosporins
7.4 Glycopeptide
7.5 Ketolide
7.6 Lipopeptide
7.7 Macrolides
7.8 Penicillins
7.9 Oxazolidinones
7.10 Pleuromutilins
7.11 Quinolone

8 LEADING BRANDS
8.1 Aminogylcoside Antibiotics
8.1.1 Tygacil (Wyeth)
8.1.2 Leading Aminoglycoside Sales Forecasts
8.2 Carbapenem Antibiotics
8.2.1 Finibax (Shionogi/ Johnson & Johnson/[Peninsula])
8.2.2 Merrem/Meronem (AstraZeneca/Sumitomo Pharmaceuticals)
8.2.3 Primaxin/Tieman (Merck & Co.)
8.2.4 Leading Carbapenem Sales Forecasts
8.3 Cephalosporins
8.3.1 Ceftin/Zinnat (GlaxoSmithKline)
8.3.2 Flumarin (Shionogi)
8.3.3 Omnicef/Cefzon (Abbott Laboratories/Astellas)
8.3.4 Rocephin (Roche)
8.3.5 Leading Cephalosporin Sales Forecasts
8.4 Glycopeptide Antibiotics
8.4.1 Vancomycin (Shionogi/ViroPharm/[Eli Lilly])
8.4.2 Targocid (Sanofi-Aventis/Astellas)
8.4.3 Leading Glycopeptide Sales Forecasts
8.5 Ketolide Antibiotics
8.5.1 Ketek (Sanofi-Aventis/Astellas)
8.5.2 Leading Ketolide Sales Forecasts
8.6 Lipopeptide Antibiotics
8.6.1 Cubicin (Cubist Pharmaceuticals/Novartis)
8.6.2 Leading Lipopeptide Sales Forecasts
8.7 Macrolide Antibiotics
8.7.1 Biaxin/Biaxin XL (Abbott Laboratories)
8.7.2 Zithromax/Zmax (Pfizer)
8.7.3 Macrolide Sales Forecasts
8.8 Oxazolidinone Antibiotics
8.8.1 Zyvox/Zyvoxid (Pfizer)
8.8.2 Leading Oxazolidinone Sales Forecasts
8.9 Penicillin Antibiotics
8.9.1 Augmentin (GlaxoSmithKline)
8.9.2 Zosyn/Tazocin (Wyeth)
8.9.3 Leading Penicillin Sales Forecasts
8.10 Quinolone Antibiotics
8.10.1 Avelox/Avalox (Astellas/Bayer/Schering-Plough)
8.10.2 Levaquin/Cravit and Floxin/Tarivid (Johnson & Johnson/Daiichi Sankyo/Santen Pharmaceuticals)
8.10.3 Cipro/Ciprobay/Ciproxin (Bayer/Schering-Plough)
8.10.4 Leading Quinolone Sales Forecasts
8.11 Pleuromutilin Antibiotics
8.11.1 Altabax/Altargo (GlaxoSmithKline)
8.11.2 Leading Pleuromutilin Sales Forecasts
8.12 Other Antibiotics
8.13 Global Antibacterial Sales Forecasts

9 FUTURE BRANDS
9.1 Carbapenem Antibiotics
9.1.1 Faropenem Medoxomil (Replidyne)
9.1.2 PF-3,709,270 (Pfizer)
9.1.3 R1558 (Roche/Daiichi-Sankyo)
9.2 Cephalosporin Antibiotics
9.2.1 Ceftobiprole (J&J/[Basilea])
9.2.2 Ceftaroline (Cerexa/[Takeda])
9.3 Dihydrofolate Reductase Inhibitor Antibiotics
9.3.1 Iclaprim (Arpida/[Roche])
9.3.2 AR-709 (Arpida)
9.4 Glycopeptide Antibiotics
9.4.1 Oritavancin (Targanta/[InterMune])
9.4.2 Telavancin (Astellas/Theravance)
9.4.3 Zeven (Pfizer/[Vicuron Pharmaceuticals])
9.5 Ketolide Antibiotics
9.5.1 Cethromycin (Advanced Life Sciences/[Abbott])
9.6 Macrolides
9.6.1 S-013420 (Shionogi/[Enanta Pharmaceuticals])
9.6.2 Quinolone
9.6.3 ABT-492 (Abbott/[Wakunga Pharmaceuticals])
9.6.4 DX-619 (Daiichi-Sankyo)
9.6.5 Gracevit (Daiichi-Sankyo)
9.6.6 Garenoxacin (Schering-Plough/[Toyama])
9.6.7 Olamufloxacin (Abbott)
9.7 Other Antibiotics
9.7.1 Aurograb (Novartis/[NeuTec])
9.7.2 Tifacogin (Novartis/[Chiron])
9.7.3 REP8839 (Replidyne)
9.8 Future Global Antibacterial Sales Forecasts

10 KEY COMPANY PROFILES
10.1 Advanced Life Sciences
10.2 Arpida Ltd
10.3 Basilea Pharmaceutica AG
10.4 Cerexa Inc.
10.5 Cubist Pharmaceuticals, Inc.
10.6 Targanta Therapeutics Corp.
10.7 Theravance

APPENDIX 3: Acronyms

TABLES
Table 2.1 Infectious Disease Leading Worldwide Health Burden
Table 4.1 Potential for Clinical Success
Table 6.1 Historical Sales of Leading Antibiotics 2001-2005
Table 7.1 Different Classes of Antibacterial Agents
Table 8.1 Common Bacterial Infections
Table 8.2 Sales Forecasts of Leading Aminoglycosides US$mn 2005A – 2012E
Table 8.3 Sales Forecasts of Leading Carbapenems US$2005-2012E
Table 8.4 Approved Cephalosporin Antibiotics
Table 8.5 Sales Forecasts of Cephalosporins US$mn 2005-2012E
Table 8.6 Sales Forecasts of Leading Glycopeptides US$mn 2005A – 2012E
Table 8.7 Sales Forecasts of Ketolide Antibiotics US$mn 2005 – 2012E
Table 8.8 Clinical Efficacy of Cubicin Versus Comparator on Pathogens
Table 8.9 Sales Forecasts of Leading Lipopeptides US$mn 2005A – 2012E
Table 8.10 Sales Forecasts of Leading Macrolides US$m 2005A – 2012E
Table 8.11 Sales Forecasts of Leading Oxazolidinones US$m 2005A – 2012E
Table 8.12 Approved Penicillins
Table 8.13 Sales Forecasts of Leading Penicillins US$m 2005A – 2012E
Table 8.14 Approved Quinolone Antibiotics
Table 8.15 Sales Forecasts of Leading Quinolones US$m 2005A – 2012E
Table 8.16 Sales Forecasts of Leading Pleuromutilins US$m 2005A – 2012E
Table 8.17 Sales Summary of Leading Antibacterial Agents (US$m) 2005 – 2012E
Table 9.1 Antibiotics in Clinical Development
Table 9.2 DX-619 Potent Quinolone in Vitro Against Gram Positive Pathogens
Table 9.3: Sales Summary of New Antibacterial Agents (US$m) 2005 – 2012E

FIGURES
Figure 3.1 MRSA Among ICU Patients in the US, 1995-2004
Figure 6.1 Global Anti-Infective Market 2006
Figure 6.2 Global Anti-Infective Market 2015
Figure 6.3 Antibacterial Sales Split – Drug Class Split 2006
Figure 6.4 Cephalosporin Antibiotics – Leading Drugs 2006
Figure 6.5 Macrolide Antibiotics – Leading Drugs 2006
Figure 6.6 Penicillin Antibiotics – Leading Drugs 2006
Figure 6.7 Quinolone Antibiotics – Leading Drugs 2006
Figure 6.8 Other Antibiotics – Leading Drugs 2006
Figure 6.9 The Major Players 2006
Figure 6.10 The Major Players 2012
Figure 6.11 Antibacterial Agents – Drug Class Split 2012
Figure 7.1 Site of Action of Leading Antibacterial Agents
Figure 9.1 Number of Drugs in Development to Treat Infectious Diseases
Figure 9.2 Schematic of Drug-resistant Pathogens and Market Opportunities
Figure 9.3 DX-619 Effective in Severe Infection Models Potent Quinolone in Vitro Against Gram Positive Pathogens
Figure 9.4 DC-159a Effective in Severe RTI